ABUS - Arbutus Biopharma: Focused On HBV With A Potentially Huge Litigation 'Wildcard'

2024-07-05 07:01:12 ET

Summary

• Today, we take a deeper look at Arbutus Biopharma Corporation, who is focused on developing better treatments for HBV.
• The company also is locked in litigation against Covid-19 vaccine makers like Moderna that could eventually deliver substantial upside if the company is victorious.
• An analysis of Arbutus Biopharma follows in the paragraphs below.

Today, we are putting clinical stage Arbutus Biopharma Corporation ( ABUS ) in the spotlight. The stock has been on a nice run since the stock market bottomed out late last October after a bit of a summer swoon. The company has several candidates it is developing within its pipeline and has potential and substantial upside from a key litigation dispute. An analysis follows below....

For further details see: